<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02819687</url>
  </required_header>
  <id_info>
    <org_study_id>RDX5791-101</org_study_id>
    <nct_id>NCT02819687</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RDX5791 in Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses of RDX5791 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ardelyx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ardelyx</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase I, single-center, randomized, double-blind, placebo-controlled study to evaluate the
      safety, tolerability, pharmacokinetics, and pharmacodynamics of single-and multiple-ascending
      doses of RDX5791 in healthy male and female subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the single-ascending dose (SAD), 5 separate cohorts received RDX5791 at various doses once
      po fasting. Each cohort of 8 subjects (6 RDX5791, 2 placebo) received a diet standardized fro
      Na+ content wile in the clinical pharmacology unit (CPU).

      The PK data from the 50-mg dose and the safety data from the 150-mg dose of the SAD study
      were evaluated prior to proceeding with the multiple-ascending dose (MAD) phase. Doses of
      RDX5791 are 3, 10, 30, and 100 mg administered once daily po fasting. Four cohorts of 10
      subjects each (8 RDX5791, 2 placebo) received a diet standardized for Na+ content while in
      the CPU.

      Safety assessments including clinical assessment and vital signs, clinical laboratory
      evaluations, ECGs, and AE monitoring were performed at regular intervals. Plasma was
      collected at regular intervals for PK analysis. The PD assessment included stool frequency
      and consistency, as well as changes in urinary Na+ excretion. All bowel movements were
      collected and analyzed for Na+ content outside this study protocol.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>7 days</time_frame>
    <description>serum chemistry and hematology, ECGs, and clinical signs and symptoms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of RDX5791</measure>
    <time_frame>7 days</time_frame>
    <description>blood levels of drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary and fecal sodium levels</measure>
    <time_frame>7 days</time_frame>
    <description>to assess the pharmacodynamics of RDX5791</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary and fecal phosphorus levels</measure>
    <time_frame>7 days</time_frame>
    <description>to assess the pharmacodynamics of RDX5791</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>RDX5791 10mg QD (SAD phase)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10mg of RDX5791 administered once daily PO fasting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RDX5791 50mg QD (SAD phase)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50mg of RDX5791 administered once daily PO fasting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RDX5791 150mg QD (SAD phase)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150mg of RDX5791 administered once daily PO fasting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RDX5791 450mg QD (SAD phase)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>450mg of RDX5791 administered once daily PO fasting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RDX5791 900mg QD (SAD phase)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>900mg of RDX5791 administered once daily PO fasting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RDX5791 3mg QD (MAD phase)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3mg of RDX5791 administered once daily PO fasting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RDX5791 10mg QD (MAD phase)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10mg of RDX5791 administered once daily PO fasting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RDX5791 30 mg QD (MAD phase)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30mg of RDX5791 administered once daily PO fasting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RDX5791 100 mg QD (MAD phase)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100mg of RDX5791 administered once daily PO fasting</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RDX5791</intervention_name>
    <arm_group_label>RDX5791 10mg QD (SAD phase)</arm_group_label>
    <arm_group_label>RDX5791 50mg QD (SAD phase)</arm_group_label>
    <arm_group_label>RDX5791 150mg QD (SAD phase)</arm_group_label>
    <arm_group_label>RDX5791 450mg QD (SAD phase)</arm_group_label>
    <arm_group_label>RDX5791 900mg QD (SAD phase)</arm_group_label>
    <arm_group_label>RDX5791 3mg QD (MAD phase)</arm_group_label>
    <arm_group_label>RDX5791 10mg QD (MAD phase)</arm_group_label>
    <arm_group_label>RDX5791 30 mg QD (MAD phase)</arm_group_label>
    <arm_group_label>RDX5791 100 mg QD (MAD phase)</arm_group_label>
    <other_name>Tenapanor</other_name>
    <other_name>AZD1722</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>RDX5791 10mg QD (SAD phase)</arm_group_label>
    <arm_group_label>RDX5791 50mg QD (SAD phase)</arm_group_label>
    <arm_group_label>RDX5791 150mg QD (SAD phase)</arm_group_label>
    <arm_group_label>RDX5791 450mg QD (SAD phase)</arm_group_label>
    <arm_group_label>RDX5791 900mg QD (SAD phase)</arm_group_label>
    <arm_group_label>RDX5791 3mg QD (MAD phase)</arm_group_label>
    <arm_group_label>RDX5791 10mg QD (MAD phase)</arm_group_label>
    <arm_group_label>RDX5791 30 mg QD (MAD phase)</arm_group_label>
    <arm_group_label>RDX5791 100 mg QD (MAD phase)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI between 18 and 29.9 kg/m², inclusive

          -  Females must be of non-childbearing potential; If of child-bearing potential, must
             have negative pregnancy test and confirm the use of one of the appropriate means of
             contraception

          -  Males must agree to use appropriate methods of barrier contraception or have
             documented surgical sterilization

        Exclusion Criteria:

          -  Diagnosis or treatment of any clinically symptomatic biochemical or structural
             abnormality of the GI tract

          -  Any surgery on the small intestine or colon, excluding appendectomy

          -  Loose stools (Bristol Stool Form Score of 6 or 7) ≥2 days in the past 7 days

          -  Hepatic dysfunction ([ALT] or [AST]) &gt;1.5 times the upper limit of normal or renal
             impairment

          -  Any evidence of or treatment of malignancy, excluding non-melanomatous malignancies of
             the skin

          -  Use of diuretic medications, medications that are known to affect stool consistency
             and/or GI motility

          -  Use of an investigational agent within 30 days prior to Day -2

          -  Positive virology, alcohol, or drugs of abuse test during screening

          -  Use of any prescription medication within 7 days before admission to the CPU

          -  Have had significant blood loss (&gt;450 mL) or have donated 1 or more units of blood or
             plasma within 8 weeks prior to study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David P. Rosenbaum, Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>Ardelyx, Inc.</affiliation>
  </overall_official>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2016</study_first_submitted>
  <study_first_submitted_qc>June 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2016</study_first_posted>
  <last_update_submitted>June 29, 2016</last_update_submitted>
  <last_update_submitted_qc>June 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase I</keyword>
  <keyword>Healthy</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

